Literature DB >> 18246805

[Modified frontolateral partial larnygectomy without tracheostomy for early laryngeal cancer of the true vocal cord].

Pin Dong1, Qiang Wang, Xiao-Yan Li, Li Li, Li Chen, Guo-Liang Wang, Xin-Wei Chen.   

Abstract

OBJECTIVE: To investigate the feasibility of modified frontolateral partial laryngectomy without tracheostomy in the treatment for early laryngeal cancer or severe atypical hyperplasia of the true vocal cord.
METHODS: A retrospective analysis of 41 patients treated in the past 6 years with modified frontolateral partial laryngectomy without tracheostomy was carried out. There were 39 early laryngeal cancers of the lateral vocal cord with 34 in T1a stage and 5 in T2, and the remain 2 patients had severe atypical hyperplasia of the lateral vocal cord. An ipsilateral false vocal cord flap was used in 39 patients and cervical skin flap in 2 to reconstruct the defect after resection of the true vocal cord. In order to get a large laryngeal cavity, a reverted sternohyoid fascia was used to cover the front area, which made the new laryngeal lumen become ladder-shaped.
RESULTS: The incisions of all 41 patients healed up by first intention. The only postoperative complication was subcutaneous emphysema, which developed postoperatively in 9 patients, but subsided prior to discharge. The estimated 1-, 3- and 5-year survival rates were all 100%. No patients died during the postoperative period.
CONCLUSION: Modified frontolateral partial laryngectomy without tracheostomy is effective with a high rate of success in eradicating early or selected invasive glottic squamous cell carcinoma or severe atypical hyperplasia of the true vocal cord.

Entities:  

Mesh:

Year:  2007        PMID: 18246805

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  1 in total

1.  An empirical study of modified frontolateral partial laryngectomy without tracheotomy.

Authors:  Hongming Xu; Pin Dong; Zhenfeng Sun; Jin Xie
Journal:  Exp Ther Med       Date:  2012-11-28       Impact factor: 2.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.